Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 21 resultados

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE MILTENYI BIOTEC BV CO KG participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

NANO4TALENT: Post doctoral talent attraction programme to boost research career in the field of nanomaterials for... NANO4TALENT is an ambitious international transboundary Postdoctoral Programme that will award 5 postdoctoral positions of 24 months each in...
2024-08-16 - 2029-12-31 | Financiado

T-RAFIC: Training network for tracking and controlling therapeutic immune cells in cancer Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerat...
2024-07-16 - 2029-03-31 | Financiado

ARTiDe: Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe) MILTENYI BIOTEC BV CO KG participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, a...
2023-04-27 - 2028-06-30 | Financiado

T-FITNESS: FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS MILTENYI BIOTEC BV CO KG participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Cell and gene therapies offer a massive paradigm shift from current treatment options and hold the potential to cure previously untreatable...
2022-07-08 - 2026-08-31 | Financiado

FAIR CHARM: Fast Infrared Coherent Harmonic Microscopy MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-ICT-2018-20 The emergence of innovative research avenues in biomedicine in the last decades (cell therapy, cancer immunotherapy, bio-nanotechnology) has...
2021-12-15 - 2025-12-31 | Financiado

REAP: Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and phot... MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-ICT-2018-20 Cancer treatment faces a major problem: it ultimately stops working for many patients because the tumor becomes resistant. The cellular orig...
2020-12-01 - 2025-06-30 | Financiado

T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado

T-OP: Training Network for Optimizing Adoptive T cell Therapy of Cancer MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-MSCA-ITN-2020 Over the last years, immunotherapy – using a patient’s own immune system to fight tumours – has emerged as an important complement to standa...
2020-08-27 - 2025-02-28 | Financiado

NSC-Reconstruct: Novel Strategies for Cell based Neural Reconstruction MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-SC1-BHC-2018-2020 Neurodegenerative diseases and brain injuries affect large patient groups and carry large unmet clinical needs. NSC-Reconstruct will respond...
2019-12-11 - 2024-12-31 | Financiado

HUGODECA: Human Gonad Developmental Cell Atlas MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-SC1-BHC-2018-2020 The single ground-breaking goal of the HUGODECA project is to describe the cellular composition and organization of the developing human gon...
2019-11-24 - 2022-06-30 | Financiado

ZENITH: ZEbrafish Neuroscience Interdisciplinary Training Hub MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-MSCA-ITN-2018 A fundamental challenge for Neuroscience is to understand how neural circuits process information from the outside world and internal physio...
2019-11-18 - 2024-03-31 | Financiado

INsTRuCT: INnovative Training in Myeloid Regulatory Cell Therapy MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-MSCA-ITN-2019 Cell therapy is an active area of immunological research and represents a highly innovative and rapidly expanding sector of pharmaceutical i...
2019-08-19 - 2024-06-30 | Financiado

RESTORE: RESTORE Health by Advanced Therapies Advanced Therapy Medicinal Products and Biologized Medical Dev... MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-FETFLAG-2018-2020 Recently, a new class of living drugs has been developed – Advanced Therapies which aim to transform the current focus of treatment of disea...
2019-02-08 - 2020-07-31 | Financiado

EUROoC: Interdisciplinary training network for advancing Organ on a chip technology in Europe MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-MSCA-ITN-2018 EUROoC will create a trans-European network of industrially oriented specialists fully trained in development and application of the emergin...
2018-08-21 - 2023-05-31 | Financiado

ENDONANO: Quantitative detection of bacterial endotoxin by novel nanotechnological approaches MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-MSCA-ITN-2018 ENDONANO (Quantitative detection of bacterial endotoxin by novel nanotechnological approaches) addresses a key regulatory and safety issue,...
2018-07-19 - 2023-06-30 | Financiado

MATURE-NK: MAnufacturing of TUmour REactive Natural Killer cells MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-MSCA-ITN-2017 "This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied dev...
2018-05-18 - 2022-11-30 | Financiado

TRACE: Transfer of multivirus specific T cells following transplantation MILTENYI BIOTEC BV CO KG participó en un H2020: H2020-SC1-2016-2017 Allogeneic stem cell transplantation (HSCT) is a curative treatment for a variety of diseases. Viral infections such as Cytomegalovirus (CMV...
2017-12-05 - 2024-03-31 | Financiado

CARAT: Chimeric Antigen Receptors CARs for Advanced Therapies MILTENYI BIOTEC BV CO KG tramitó un H2020: H2020-PHC-2014-2015 Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that...
2015-12-08 - 2019-12-31 | Financiado